Breathe Well Live Well
|
ViroPharma Announces Six Upcoming Presentations of Cinryze(TM) (C1 Esterase …
MarketWatch (press release) There can be no assurance that that the data presented during the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) … |
View full post on asthma – Google News
|
Acton Pharmaceuticals, Inc. Submits NDA Supplement to FDA for AEROSPAN(R …
MarketWatch (press release) AEROSPAN is a hydrofluoroalkane (HFA) propelled inhaled corticosteroid for the treatment of asthma, which will compete in the $7 billion US inhaled steroid … |
View full post on asthma – Google News
|
MedicNova Announces Poster Presentations at Annual Meeting of the American …
MarketWatch (press release) The presentations are related to MediciNova's development of MN-221 for potential utility in acute exacerbations of asthma or chronic obstructive pulmonary … |
View full post on asthma – Google News
|
SOHM India Targets $600 Million Generic Drug Market for Asthma and Respiratory …
MarketWatch (press release) Allergic respiratory disorders, in particular asthma, have recorded abnormally high levels in India. Even though genetic predisposition is one of the main … |
View full post on asthma – Google News
|
Theravance Reports Third Quarter 2010 Financial Results
MarketWatch (press release) "The RELOVAIR(TM) Phase 3 programs in COPD and asthma are progressing well and have now enrolled over 8000 patients. Last month, preclinical and Phase 2a … |
View full post on asthma – Google News
|
MediciNova's MN-166 Program Recognized as One of Windhover's Top 10 …
MarketWatch (press release) Ibudilast is marketed in Japan and South Korea for the treatment of asthma and cerebrovascular disorders for which MediciNova discovered its potential as a … |
View full post on asthma – Google News
|
Clinical Data, Inc. Presents Data from Phase I Studies of Stedivaze(TM …
MarketWatch (press release) Currently available adenosine agonists must be used with caution or are contraindicated in patients with asthma and COPD. The findings, presented at the … Clinical Data Reveals Positive Results From Early-stage Trials Of Stedivaze … |
View full post on asthma – Google News
|
GSK and Theravance announce combination ICS/LABA Phase II results in the …
MarketWatch (press release) Our ongoing collaboration with GSK includes the Phase III programmes in both COPD and asthma, which are already underway for Relovair and its components. … Theravance Announces Results From Phase II Study For Developmental Combination … |
View full post on asthma – Google News
|
For the Treatment of Asthma, Surveyed Safety-Minded Physicians May Be the Most …
MarketWatch (press release) According to the new report, Brand Perception Series: Physician Segmentation in Asthma, physicians report the greatest need in asthma treatment is for a … |
View full post on asthma – Google News
|
Theravance Announces Data From the RELOVAIR(TM) Program to Be Presented at the …
MarketWatch (press release) A total of 13 preclinical and clinical abstracts for RELOVAIR(TM) and its individual components in COPD and asthma were accepted by ERS for presentation, … |
View full post on asthma – Google News